{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:57:40Z","timestamp":1788839860118,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.pcad.2025.08.010","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T15:50:10Z","timestamp":1756828210000},"page":"192-200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Comparative effectiveness of sodium-glucose cotransporter 2 inhibitors along with colchicine versus colchicine alone among coronary artery disease and type 2 diabetes patients"],"prefix":"10.1016","volume":"92","author":[{"given":"Vikash","family":"Jaiswal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Hanif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danisha","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusra","family":"Mashkoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsi","family":"Garimella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahas Reddy","family":"Jitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushar","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raheel","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jishanth","family":"Mattumpuram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Qamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J.","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2025.08.010_bb0010","first-page":"9","article-title":"Colchicine and coronary heart disease risks: a meta-analysis of randomized controlled clinical trials","author":"Ma","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"36","key":"10.1016\/j.pcad.2025.08.010_bb0015","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes [published correction appears in Eur heart J. 2025;46(16):1565. Doi:10.1093\/eurheartj\/ehaf079.]","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.pcad.2025.08.010_bb0020","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the Management of Patients with Chronic Coronary Disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on clinical practice guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"issue":"26","key":"10.1016\/j.pcad.2025.08.010_bb0025","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pcad.2025.08.010_bb0030","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.pcad.2025.08.010_bb0035","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.pcad.2025.08.010_bb0040","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.pcad.2025.08.010_bb0045","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa2405922","article-title":"Colchicine in acute myocardial infarction","volume":"392","author":"Jolly","year":"2025","journal-title":"N Engl J Med"},{"issue":"7624","key":"10.1016\/j.pcad.2025.08.010_bb0055","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.pcad.2025.08.010_bb0060","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/cbin.10988","article-title":"Colchicine, a microtubule-disassembling drug, in the therapy of cardiovascular diseases","volume":"42","author":"Chaldakov","year":"2018","journal-title":"Cell Biol Int"},{"issue":"0","key":"10.1016\/j.pcad.2025.08.010_bb0065","doi-asserted-by":"crossref","first-page":"105","DOI":"10.14748\/bmr.v28.4456","article-title":"Colchicine, inflammation and fibrosis in cardiovascular disease: merging three classical Tales","volume":"28","author":"Chaldakov","year":"2018","journal-title":"Biomedical Reviews"},{"issue":"1","key":"10.1016\/j.pcad.2025.08.010_bb0070","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-reactive protein to Interleukin-6 to Interleukin-1: moving upstream to identify novel targets for Atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ Res"},{"issue":"38","key":"10.1016\/j.pcad.2025.08.010_bb0075","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab anti-inflammatory thrombosis outcomes study (CANTOS)","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.pcad.2025.08.010_bb0080","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.amjcard.2006.10.039","article-title":"Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease","volume":"99","author":"Nidorf","year":"2007","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2025.08.010_bb0085","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/jama.286.1.64","article-title":"Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation\/CRP evaluation (PRINCE): a randomized trial and cohort study","volume":"286","author":"Albert","year":"2001","journal-title":"JAMA"},{"issue":"26","key":"10.1016\/j.pcad.2025.08.010_bb0090","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","article-title":"Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events","volume":"344","author":"Ridker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2025.08.010_bb0095","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijcard.2019.01.054","article-title":"Effect of short-term colchicine treatment on endothelial function in patients with coronary artery disease","volume":"281","author":"Kajikawa","year":"2019","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.pcad.2025.08.010_bb0100","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine--Update on mechanisms of action and therapeutic uses","volume":"45","author":"Leung","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"19","key":"10.1016\/j.pcad.2025.08.010_bb0105","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.pcad.2025.08.010_bb0110","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1093\/eurheartj\/ehab115","article-title":"Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials","volume":"42","author":"Fiolet","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2025.08.010_bb0115","article-title":"Efficacy of colchicine for prevention of stroke and adverse cardiovascular events: a Meta-analysis of 16 randomized controlled trials","author":"Jaiswal","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.pcad.2025.08.010_bb0120","first-page":"13","article-title":"Sodium glucose cotransporter type 2 inhibitors improve Cardiorenal outcome of patients with coronary artery disease: a Meta-analysis","author":"Wei","year":"2022","journal-title":"Front Endocrinol"},{"issue":"11","key":"10.1016\/j.pcad.2025.08.010_bb0125","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s13300-023-01454-w","article-title":"Treatment with SGLT2 inhibitors in patients with diabetes mellitus and extensive coronary artery disease: mortality and cardiovascular outcomes","volume":"14","author":"Chipayo-Gonzales","year":"2023","journal-title":"Diabetes Ther"},{"issue":"10","key":"10.1016\/j.pcad.2025.08.010_bb0130","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"issue":"6S","key":"10.1016\/j.pcad.2025.08.010_bb0135","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.amjmed.2017.04.009","article-title":"Cardiovascular protection by sodium glucose cotransporter 2 inhibitors: potential mechanisms","volume":"130","author":"Staels","year":"2017","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.pcad.2025.08.010_bb0140","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ejhf.1708","article-title":"Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure","volume":"22","author":"Butler","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.pcad.2025.08.010_bb0145","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/00325481.2019.1581971","article-title":"SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses","volume":"131","author":"Filippatos","year":"2019","journal-title":"Postgrad Med"},{"issue":"20","key":"10.1016\/j.pcad.2025.08.010_bb0150","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013389","article-title":"SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects","volume":"8","author":"Lam","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"10.1016\/j.pcad.2025.08.010_bb0155","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/0735-1097(92)90624-V","article-title":"Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty","volume":"19","author":"O\u2019Keefe","year":"1992","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.pcad.2025.08.010_bb0160","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/ejhf.933","article-title":"The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors","volume":"19","author":"Butler","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"10.1016\/j.pcad.2025.08.010_bb0165","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/jamacardio.2020.6827","article-title":"Associations of Empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: a substudy of the Empire HF randomized clinical trial","volume":"6","author":"Omar","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"5","key":"10.1016\/j.pcad.2025.08.010_bb0170","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1536\/ihj.22-151","article-title":"Different doses of Empagliflozin in patients with heart failure with reduced ejection fraction","volume":"63","author":"Hao","year":"2022","journal-title":"Int Heart J"},{"issue":"3","key":"10.1016\/j.pcad.2025.08.010_bb0175","first-page":"388","article-title":"A dose comparison study of Empagliflozin in patients with heart failure with preserved ejection fraction","volume":"40","author":"MacDonald","year":"2024","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.pcad.2025.08.010_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2021.110206","article-title":"Dapagliflozin alleviates advanced glycation end product induced podocyte injury through AMPK\/mTOR mediated autophagy pathway","volume":"90","author":"Yang","year":"2022","journal-title":"Cell Signal"},{"issue":"1","key":"10.1016\/j.pcad.2025.08.010_bb0185","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","article-title":"The effect of dapagliflozin treatment on epicardial adipose tissue volume","volume":"17","author":"Sato","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"10.1016\/j.pcad.2025.08.010_bb0190","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.cardfail.2017.09.014","article-title":"Contemporary epidemiology, management, and outcomes of patients hospitalized for heart failure in China: results from the China heart failure (China-HF) registry","volume":"23","author":"Zhang","year":"2017","journal-title":"J Card Fail"},{"issue":"1","key":"10.1016\/j.pcad.2025.08.010_bb0195","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00228-023-03582-5","article-title":"Empagliflozin and colchicine in patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction: a randomized, double-blinded, three-arm parallel-group, controlled trial","volume":"80","author":"Khiali","year":"2024","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003306202500132X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003306202500132X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T05:08:37Z","timestamp":1763183317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003306202500132X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":37,"alternative-id":["S003306202500132X"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2025.08.010","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness of sodium-glucose cotransporter 2 inhibitors along with colchicine versus colchicine alone among coronary artery disease and type 2 diabetes patients","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2025.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}